Ashkon Software



CNAT - Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc. logo Conatus Pharmaceuticals Inc. (CNAT) was a clinical-stage biopharmaceutical company that focused on the development of treatments for chronic liver diseases. The company's lead product candidate was emricasan, a first-in-class, orally active pan-caspase inhibitor that was being developed for the treatment of nonalcoholic steatohepatitis (NASH), liver cirrhosis, and other liver diseases.

Emricasan was designed to inhibit the activation of caspases, which are enzymes that play a key role in the progression of liver disease. By inhibiting caspase activation, emricasan was intended to reduce liver cell death and inflammation, which can contribute to the progression of liver disease.

Conatus Pharmaceuticals conducted several clinical trials of emricasan in patients with NASH, liver cirrhosis, and other liver diseases. However, in 2020, the company announced that it was winding down its operations and would be liquidating its assets. As a result, it appears that the development of emricasan and other product candidates has been discontinued.

Conatus Pharmaceuticals was founded in 2005 and was based in San Diego, California. The company was listed on the NASDAQ stock exchange under the ticker symbol CNAT. The company's liquidation and dissolution plan was approved by its shareholders in




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer